A Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Efficacy of docetaxel and celecoxib by PSA response defined as a 50% reduction in PSA maintained on two consecutive evaluations at least 4 weeks apart
two consecutive evaluations at least 4 weeks apart
Jaderson Lima, M.D.
Brazil: National Health Surveillance Agency